Aclaris Therapeutics, Inc. (ACRS) is preparing to release new clinical results for two of its lead immuno-inflammatory drug candidates, marking an important update in the company's biologic and oral inhibitor pipeline.
The company announced that it will provide full results from its Phase 1a single-and multiple-ascending-dose study of ATI-052- its anti-TSLP/IL-4R bispecific antibody- along with the lead indication selection for ATI-2138, an ITK/JAK3 inhibitor. Both updates will be shared before the U.S. financial markets open on April 28, 2026, at 8:30 AM EST.
ACRS has traded between $1.16 and $4.89 over the past year. The stock closed Monday's trading at $4.41, up 2.56%. During overnight trading, the stock traded at $4.55, up 3.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.